Ocular angiogenesis: Vascular endothelial growth factor and other factors

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 28-37

  Rubio, Roman G ^a   Adamis, Anthony P ^b  

^a Avalanche Biotechnologies   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGPT2 PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

COMPLEMENT ALTERNATIVE PATHWAY; EYE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANGIOPOIETIN-2; COMPLEMENT PATHWAY, ALTERNATIVE; EYE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-SIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947230526     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000431129     Document Type: Article

References (62)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Shibuya M: Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153:13-19.
3. Adamis AP: Ocular angiogenesis: vascular endothelial growth factor and other factors; in Nguyen QD, Rodrigues EB, Farah ME, Mieler WF (eds): Retinal Pharmacotherapy. Philadelphia, Saunders, 2010, pp 23-36.
4. Campochiaro PA: Ocular neovascularization. J Mol Med (Berl) 2013; 91:311-321.
5. Li X, Kumar A, Zhang F, Lee C, Tang Z: Complicated life, complicated VEGF-B. Trends Mol Med 2012; 18:119-127.
6. Puddu A, Sanguineti R, Durante A, Nicolo M, Viviani GL: Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis 2012; 18:2509-2517.
7. Rakic J-M, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart J-M, Noel A, Munaut C: Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3186-3193.
8. Kowalczuk L, Touchard E, Omri S, Jonet L, Klein C, Valamanes F, Berdugo M, Bigey P, Massin P, Jeanny J-C, Behar-Cohen F: Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One 2011; 6.
9. Deissler HL, Deissler H, Lang GK, Lang GE: VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp Eye Res 2013; 115:162-171.
10. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155:429-437.e7.
11. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R: Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO Study. Ophthalmology 2014; 121:202-208.
12. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS: Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121:193-201.
13. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006; 312:630-641.
14. Fiedler U, Augustin HG: Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-558.
15. Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, Shioi G, Chang W, Suda T, Mochizuki N, Nakaoka Y, Komuro I, Yoo OJ, Koh GY: Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci Transl Med 2013; 5:203ra127.
16. Pfaff D, Fiedler U, Augustin HG: Emerging roles of the angiopoietin-Die and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol 2006; 80:719-726.
17. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y: Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999; 40:1912-1920.
18. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H: Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139:476-481.
19. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A: A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52:3784-3791.
20. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83:233-240.
21. Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, Boyd SR, Joussen AM, Ziemssen F, Hykin PG, Moss SE: Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine 2007; 40:144-150.
22. Nakajima T, Nakajima E, Shearer TR, Azuma M: Concerted inhibition of HIF-1α and-2α expression markedly suppresses angiogenesis in cultured RPE cells. Mol Cell Biochem 2013; 383:113-122.
23. Kumar R, Harris-Hooker S, Kumar R, Sanford G: Co-culture of retinal and endothelial cells results in the modulation of genes critical to retinal neovascularization. Vasc Cell 2011; 3:27.
24. Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JKJ, Baumann M, Shen J, Iwase T, Tian J, Stevens R, Hackett SF, Stumpp MT, Campochiaro PA: Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2014; 17:553-562.
25. Dong A, Xie B, Shen J, Yoshida T, Yokoi K, Hackett SF, Campochiaro PA: Oxidative stress promotes ocular neovascularization. J Cell Physiol 2009; 219:544-552.
26. Vinores SA, Xiao W-H, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiaro PA: Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006; 206:749-758.
27. Donoso LA, Kim D, Frost A, Callahan A, Hageman G: The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006; 51:137-152.
28. Liu X, Zhao P, Tang S, Lu F, Hu J, Lei C, Yang X, Lin Y, Ma S, Yang J, Zhang D, Shi Y, Li T, Chen Y, Fan Y, Yang Z: Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population. Retina 2010; 30:1177-1184.
29. Lyzogubov VV, Tytarenko RG, Jha P, Liu J, Bora NS, Bora PS: Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol 2010; 177:1870-1880.
30. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J: Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006; 103:2328-2333.
31. Bora PS, Sohn J-H, Cruz JMC, Jha P, Nishihori H, Wang Y, Kaliappan S, Kaplan HJ, Bora NS: Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005; 174:491-497.
32. Rohrer B, Coughlin B, Kunchithapautham K, Long Q, Tomlinson S, Takahashi K, Holers VM: The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol 2011; 48:1-8.
33. Bandyopadhyay M, Rohrer B: Matrix metalloproteinase activity creates pro-Angiogenic environment in primary human retinal pigment epithelial cells exposed to complement. Invest Ophthalmol Vis Sci 2012; 53:1953-1961.
34. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM: Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009; 50:5818-5827.
35. Loyet KM, Deforge LE, Katschke KJ, Diehl L, Graham RR, Pao L, Sturgeon L, Lewin-Koh S-C, Hollyfield JG, van Lookeren Campagne M: Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012; 53:6628-6637.
36. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT: Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 2013; 155:697-704.
37. Wang Q, Li T, Wu Z, Wu Q, Ke X, Luo D, Wang H: Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-Angiogenesis effect in vivo. PLoS One 2013; 8:e70544.
38. Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu D-C: A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011; 118:672-678.
39. Mousa SA, Mousa SS: Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 2010; 24:183-194.
40. Thiele S, Liegl RG, Konig S, Siedlecki J, Langer J, Eibl K, Haritoglou C, Kampik A, Kernt M: Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use (in German). Klin Monbl Augenheilkd 2013; 230:247-254.
41. Thill M, Berna MJ, Kunst F, Wege H, Strunnikova NV, Gordiyenko N, Grierson R, Richard G, Csaky KG: SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration. Mol Vis 2011; 17:85-98.
42. Keskin U, Totan Y, Karadag R, Erdurmus M, Aydln B: Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. Ophthalmic Res 2012; 47:13-18.
43. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE: Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008; 68:9551-9557.
44. Nowak-Sliwinska P, Storto M, Cataudella T, Ballini J-P, Gatz R, Giorgio M, van den Bergh H, Plyte S, Wagnieres G: Angiogenesis inhibition by the maleimide-based small molecule GNX-686. Microvasc Res 2012; 83:105-110.
45. Ambati J, Atkinson JP, Gelfand BD: Immunology of age-related macular degeneration. Nat Rev Immunol 2013; 13:438-451.
46. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM: A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol 2010; 703:137-149.
47. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM: Systemic human CR2-Dargeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther 2012; 28:402-409.
48. Campochiaro PA: Gene transfer for ocular neovascularization and macular edema. Gene Ther 2012; 19:121-126.
49. Han Z, Conley SM, Naash MI: AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci 2011; 52:3051-3059.
50. Keaney J, Campbell M, Humphries P: From RNA interference technology to effective therapy: how far have we come and how far to go? Ther Deliv 2011; 2:1395-1406.
51. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Khan A, Aitchison R, Erlich SS: Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 2012; 26:1099-1105.
52. Haurigot V, Villacampa P, Ribera A, Bosch A, Ramos D, Ruberte J, Bosch F: Long-Derm retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One 2012; 7:e41511.
53. Esipov RS, Beirakhova KA, Chupova LA, Likhvantseva VK, Stepanova EV, Miroshnikov AI: Recombinant fragment of pigment epithelium-derived factor (44-77) prevents pathological corneal neovascularization (in Russian). Bioorg Khim 2012; 38:78-85.
54. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17:167-176.
55. Tarallo V, Bogdanovich S, Hirano Y, Tudisco L, Zentilin L, Giacca M, Ambati J, De Falco S: Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci 2012; 53:7989-7996.
56. Owen LA, Uehara H, Cahoon J, Huang W, Simonis J, Ambati BK: Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One 2012; 7:e33576.
57. Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP: Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther 2012; 19:999-1009.
58. El Sanharawi M, Touchard E, Benard R, Bigey P, Escriou V, Mehanna C, Naud MC, Berdugo M, Jeanny JC, Behar-Cohen F: Long-Derm efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization. Gene Ther 2013; 20:1093-1103.
59. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li X-Y, Whitcup SM, Li J: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118:2453-2460.
60. Kiernan DF, Mieler WF: The use of intraocular corticosteroids. Expert Opin Pharmacother 2009; 10:2511-2525.
61. Boyer DS: Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD): results of a phase I study. Association for Research in Vision and Ophthalmology, Fort Lauderdale, 2009.
62. Dugel PU: Anti-platelet derived growth factor: where do we stand? American Academy of Ophthalmology Annual Meeting, Chicago, 2012.